Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Prof. Israel Vlodavsk

Chair of Hepalink’s Scientific Advisory Board

Doctor of Cancer Research at Machon Weizmann Lemada, Israel
Completed his postdoctoral training at UCLA and UCSF
Served as a visiting professor at Harvard University and the Memorial Sloan-Kettering Cancer Center, as well as the National University of Australia.
Currently professor at Technion Integrated Cancer Center, Israel

Prof. Israel Vlodavsky is one of the first few scientists who recognized the active role of extracellular matrix (ECM) in coordinating cellular responses to normal and pathological conditions. His discovery about ECM being a reservoir of biologically active molecules has established the foundation enabling the current search in tumor microenvironment and its role in cancer progressions. Another one of Prof. Vlodavsky’s most celebrated achievements is the cloning and encoding of heparanase which plays a key role in tissue remodeling, caner metastasis, angiogenesis, inflammations, diabetes, and renal dysfunctions. Prof. Vlodavsky is a pioneer that offered groundbreaking knowledge about and new therapies for the treatment of cancer and a range of other diseases.
Prof. Li Jin-ping

Secretary to Hepalink’s Scientific Advisory Board

Chinese scientist with Swedish nationality, and holds a PhD degree in biochemistry
Currently professor at the Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden; serves as a PhD supervisor, and Research Projects Leader
Visiting Professor at Beijing University of Chemical Technology
Elected in the 10th batch of overseas high-level talents in Beijing Overseas Talent Aggregation Project

Prof. Li Jin-ping has over 30 years of research experience in the biological function and pathophysiology of heparin and heparin sulfate and has published over 100 research papers. She is an internationally renowned expert in carbohydrate chemistry and glycobiology. Prof. Li’s research mainly focuses on the therapeutic effect of heparin and heparin sulfate in cancer, dementia, diabetes, and inflammatory diseases, in an effort to discover effective targeted therapies for these diseases.
Prof. Nathan Karin

Member of Hepalink’s Scientific Advisory Board

Doctor of Immunology at Machon Weizmann Lemada, Israel
Post-doctor at Immunology and Neuroimmunology at Stanford University
Formerly Visiting Professor at the Department of Neurology of School of Medicine, Stanford University
Currently Professor in the Department of Immunology at the Ruth and Bruce Rappaport Faculty of Medicine

Prof. Nathan Karin has worked on areas such as cancer immunology, regulation of inflammatory processes within the central nervous system, and potential mechanisms for leukocyte migration and function. His research on adhesion molecules and cell migration significantly contributed to the development of lead therapies for the treatment of multiple sclerosis, and his discovery of chemokines had led to the current understanding about chemokines and cytokines and their role in inflammatory autoimmune disease and cancer immunology.

ag真人平台官方